

Hans Törnblom

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8194984/publications.pdf>

Version: 2024-02-01

109
papers

5,301
citations

147801

31
h-index

91884

69
g-index

116
all docs

116
docs citations

116
times ranked

4497
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2017, 152, 111-123.e8.	1.3	470
2	Self-Reported Food-Related Gastrointestinal Symptoms in IBS Are Common and Associated With More Severe Symptoms and Reduced Quality of Life. <i>American Journal of Gastroenterology</i> , 2013, 108, 634-641.	0.4	469
3	Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome as Well as Traditional Dietary Advice: A Randomized Controlled Trial. <i>Gastroenterology</i> , 2015, 149, 1399-1407.e2.	1.3	463
4	Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. <i>Gastroenterology</i> , 2020, 158, 1262-1273.e3.	1.3	249
5	Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report. <i>Gastroenterology</i> , 2018, 154, 1140-1171.e1.	1.3	247
6	Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 252-262.	8.1	199
7	Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent findings from five different patient cohorts. <i>Gut</i> , 2018, 67, 255-262.	12.1	186
8	Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs. <i>Gut</i> , 2018, 67, 872-881.	12.1	176
9	Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. <i>Gut</i> , 2015, 64, 84-92.	12.1	167
10	An approach to the diagnosis and management of Rome IV functional disorders of chronic constipation. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 39-46.	3.0	148
11	Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 36-49.	17.8	147
12	Colonic Transit Time and IBS Symptoms: What's the Link?. <i>American Journal of Gastroenterology</i> , 2012, 107, 754-760.	0.4	144
13	The Prevalence and Impact of Overlapping Rome IV-Diagnosed Functional Gastrointestinal Disorders on Somatization, Quality of Life, and Healthcare Utilization: A Cross-Sectional General Population Study in Three Countries. <i>American Journal of Gastroenterology</i> , 2018, 113, 86-96.	0.4	138
14	Work Productivity and Activity Impairment in Irritable Bowel Syndrome (IBS): A Multifaceted Problem. <i>American Journal of Gastroenterology</i> , 2018, 113, 1540-1549.	0.4	127
15	Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. <i>Gut</i> , 2015, 64, 1774-1782.	12.1	97
16	Epidemiology, Clinical Characteristics, and Associations for Rome IV Functional Nausea and Vomiting Disorders in Adults. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 878-886.	4.4	93
17	How the Change in IBS Criteria From Rome III to Rome IV Impacts on Clinical Characteristics and Key Pathophysiological Factors. <i>American Journal of Gastroenterology</i> , 2018, 113, 1017-1025.	0.4	90
18	Global Cytokine Profiles and Association With Clinical Characteristics in Patients With Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2016, 111, 1165-1176.	0.4	86

#	ARTICLE	IF	CITATIONS
19	Evidence for an association of gut microbial Clostridia with brain functional connectivity and gastrointestinal sensorimotor function in patients with irritable bowel syndrome, based on tripartite network analysis. <i>Microbiome</i> , 2019, 7, 45.	11.1	83
20	Cumulative Effects of Psychologic Distress, Visceral Hypersensitivity, and Abnormal Transit on Patient-reported Outcomes in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2019, 157, 391-402.e2.	1.3	81
21	Depression and Somatization Are Associated With Increased Postprandial Symptoms in Patients With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2016, 150, 866-874.	1.3	71
22	Anxiety and depression in irritable bowel syndrome: Exploring the interaction with other symptoms and pathophysiology using multivariate analyses. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13619.	3.0	66
23	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. <i>United European Gastroenterology Journal</i> , 2021, 9, 307-331.	3.8	62
24	Management of the multiple symptoms of irritable bowel syndrome. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 112-122.	8.1	54
25	Interaction between preprandial and postprandial rectal sensory and motor abnormalities in IBS. <i>Gut</i> , 2014, 63, 1441-1449.	12.1	41
26	Lactulose Challenge Determines Visceral Sensitivity and Severity of Symptoms in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 226-233.e3.	4.4	38
27	Evidence of altered mucosa-associated and fecal microbiota composition in patients with Irritable Bowel Syndrome. <i>Scientific Reports</i> , 2020, 10, 593.	3.3	37
28	Effects of the long-term storage of human fecal microbiota samples collected in RNAlater. <i>Scientific Reports</i> , 2019, 9, 601.	3.3	36
29	Psychotropics, Antidepressants, and Visceral Analgesics in Functional Gastrointestinal Disorders. <i>Current Gastroenterology Reports</i> , 2018, 20, 58.	2.5	35
30	Symptom pattern following a meal challenge test in patients with irritable bowel syndrome and healthy controls. <i>United European Gastroenterology Journal</i> , 2013, 1, 358-367.	3.8	33
31	Human milk oligosaccharide supplementation in irritable bowel syndrome patients: A parallel, randomized, double-blind, placebo-controlled study. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13920.	3.0	32
32	Association between <i>Brachyspira</i> and irritable bowel syndrome with diarrhoea. <i>Gut</i> , 2021, 70, 1117-1129.	12.1	31
33	Food Avoidance and Restriction in Irritable Bowel Syndrome: Relevance for Symptoms, Quality of Life and Nutrient Intake. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1290-1298.e4.	4.4	31
34	Rome IV Functional Gastrointestinal Disorders and Health Impairment in Subjects With Hypermobility Spectrum Disorders or Hypermobility Ehlers-Danlos Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 277-287.e3.	4.4	29
35	Subgroups of IBS patients are characterized by specific, reproducible profiles of GI and non-GI symptoms and report differences in healthcare utilization: A population-based study. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13483.	3.0	28
36	Coping Skills Are Associated With Gastrointestinal Symptom Severity and Somatization in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1565-1571.e3.	4.4	27

#	ARTICLE	IF	CITATIONS
37	Plausibility criteria for putative pathophysiological mechanisms in functional gastrointestinal disorders: a consensus of experts. <i>Gut</i> , 2018, 67, 1425-1433.	12.1	27
38	Diet and gut microbiome interactions of relevance for symptoms in irritable bowel syndrome. <i>Microbiome</i> , 2021, 9, 74.	11.1	25
39	Systemic Inflammatory Protein Profiles Distinguish Irritable Bowel Syndrome (IBS) and Ulcerative Colitis, Irrespective of Inflammation or IBS-Like Symptoms. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 874-884.	1.9	24
40	A Distinct Faecal Microbiota and Metabolite Profile Linked to Bowel Habits in Patients with Irritable Bowel Syndrome. <i>Cells</i> , 2021, 10, 1459.	4.1	23
41	Understanding symptom burden and attitudes to irritable bowel syndrome with diarrhoea: Results from patient and healthcare professional surveys. <i>United European Gastroenterology Journal</i> , 2018, 6, 1417-1427.	3.8	22
42	Cumulative Effect of Psychological Alterations on Gastrointestinal Symptom Severity in Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2021, 116, 769-779.	0.4	22
43	Functional Dyspepsia and Severity of Psychologic Symptoms Associate With Postprandial Symptoms in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1745-1753.e1.	4.4	21
44	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14238.	3.0	21
45	Nurse-Administered, Gut-Directed Hypnotherapy in IBS: Efficacy and Factors Predicting a Positive Response. <i>American Journal of Clinical Hypnosis</i> , 2015, 58, 100-114.	0.6	20
46	Relationships between psychological state, abuse, somatization and visceral pain sensitivity in irritable bowel syndrome. <i>United European Gastroenterology Journal</i> , 2018, 6, 300-309.	3.8	20
47	Relations between food intake, psychological distress, and gastrointestinal symptoms: A diary study. <i>United European Gastroenterology Journal</i> , 2019, 7, 965-973.	3.8	19
48	Functional gastrointestinal disorders are increased in joint hypermobility-related disorders with concomitant postural orthostatic tachycardia syndrome. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13975.	3.0	19
49	Prevalence and Progression of Recurrent Abdominal Pain, From Early Childhood to Adolescence. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 930-938.e8.	4.4	19
50	Development of Irritable Bowel Syndrome Features Over a 5-year Period. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1244-1251.e1.	4.4	18
51	Factor Analysis Defines Distinct Upper and Lower Gastrointestinal Symptom Groups Compatible With Rome IV Criteria in a Population-based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1252-1259.e5.	4.4	18
52	Central sensitization and severity of gastrointestinal symptoms in irritable bowel syndrome, chronic pain syndromes, and inflammatory bowel disease. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14156.	3.0	18
53	Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population. <i>United European Gastroenterology Journal</i> , 2021, 9, 1178-1188.	3.8	18
54	Resting state functional connectivity of the pain matrix and default mode network in irritable bowel syndrome: a graph theoretical analysis. <i>Scientific Reports</i> , 2020, 10, 11015.	3.3	17

#	ARTICLE	IF	CITATIONS
55	Mortality Risk in Irritable Bowel Syndrome: Results From a Nationwide Prospective Cohort Study. <i>American Journal of Gastroenterology</i> , 2020, 115, 746-755.	0.4	17
56	The Effects of Human Milk Oligosaccharides on Gut Microbiota, Metabolite Profiles and Host Mucosal Response in Patients with Irritable Bowel Syndrome. <i>Nutrients</i> , 2021, 13, 3836.	4.1	17
57	Gluten and fructan intake and their associations with gastrointestinal symptoms in irritable bowel syndrome: A food diary study. <i>Clinical Nutrition</i> , 2021, 40, 5365-5372.	5.0	16
58	Altered intestinal antibacterial gene expression response profile in irritable bowel syndrome is linked to bacterial composition and immune activation. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13468.	3.0	15
59	Chronic Constipation as a Risk Factor for Colorectal Cancer: Results From a Nationwide, Case-Control Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1867-1876.e2.	4.4	15
60	Treatment of gastrointestinal autonomic neuropathy. <i>Diabetologia</i> , 2016, 59, 409-413.	6.3	14
61	A survey on the impact of the COVID-19 pandemic on motility and functional investigations in Europe and considerations for recommencing activities in the early recovery phase. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13926.	3.0	14
62	Associations among neurophysiology measures in irritable bowel syndrome (IBS) and their relevance for IBS symptoms. <i>Scientific Reports</i> , 2020, 10, 9794.	3.3	14
63	Within- and Between-Subject Variation in Dietary Intake of Fermentable Oligo-, Di-, Monosaccharides, and Polyols Among Patients with Irritable Bowel Syndrome. <i>Current Developments in Nutrition</i> , 2019, 3, nzy101.	0.3	13
64	Predictors of Symptom-Specific Treatment Response to Dietary Interventions in Irritable Bowel Syndrome. <i>Nutrients</i> , 2022, 14, 397.	4.1	13
65	Fasting breath H ₂ and gut microbiota metabolic potential are associated with the response to a fermented milk product in irritable bowel syndrome. <i>PLoS ONE</i> , 2019, 14, e0214273.	2.5	12
66	Adherence to diet low in fermentable carbohydrates and traditional diet for irritable bowel syndrome. <i>Nutrition</i> , 2020, 73, 110719.	2.4	12
67	Global Prevalence and Impact of Rumination Syndrome. <i>Gastroenterology</i> , 2022, 162, 731-742.e9.	1.3	12
68	Randomised clinical trial: individual versus group hypnotherapy for irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1501-1511.	3.7	12
69	Pre- and perinatal stress and irritable bowel syndrome in young adults – A nationwide register-based cohort study. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13436.	3.0	11
70	Habitual FODMAP Intake in Relation to Symptom Severity and Pattern in Patients with Irritable Bowel Syndrome. <i>Nutrients</i> , 2021, 13, 27.	4.1	11
71	Global prevalence and burden of meal-related abdominal pain. <i>BMC Medicine</i> , 2022, 20, 71.	5.5	11
72	Oesophageal symptoms are common and associated with other functional gastrointestinal disorders (FGIDs) in an English-speaking Western population. <i>United European Gastroenterology Journal</i> , 2018, 6, 1461-1469.	3.8	10

#	ARTICLE	IF	CITATIONS
73	Fecal chromogranins and secretogranins are linked to the fecal and mucosal intestinal bacterial composition of IBS patients and healthy subjects. <i>Scientific Reports</i> , 2018, 8, 16821.	3.3	10
74	Colonic mast cell numbers, symptom profile, and mucosal expression of elements of the epithelial barrier in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13701.	3.0	10
75	Patient-Specific Stress-Abdominal Pain Interaction in Irritable Bowel Syndrome: An Exploratory Experience Sampling Method Study. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00209.	2.5	10
76	Practical management of irritable bowel syndrome: a clinical review. <i>Minerva Gastroenterologica E Dietologica</i> , 2016, 62, 30-48.	2.2	10
77	Evidence-Based and Emerging Dietary Approaches to Upper Disorders of Gut-Brain Interaction. <i>American Journal of Gastroenterology</i> , 2022, 117, 965-972.	0.4	10
78	Disorders of gut-brain interaction: Highly prevalent and burdensome yet under-taught within medical education. <i>United European Gastroenterology Journal</i> , 2022, 10, 736-744.	3.8	10
79	Funding for gastrointestinal disease research in the European Union. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 593-595.	8.1	9
80	Functional Gastrointestinal Disorders and Associated Health Impairment in Individuals with Celiac Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1315-1325.e4.	4.4	9
81	Visceral sensitivity remains stable over time in patients with irritable bowel syndrome, but with individual fluctuations. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13603.	3.0	8
82	Association between pain sensitivity and gray matter properties in the sensorimotor network in women with irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14027.	3.0	8
83	Allergy-related diseases in childhood and risk for abdominal pain-related functional gastrointestinal disorders at 16-years-a birth cohort study. <i>BMC Medicine</i> , 2021, 19, 214.	5.5	8
84	Irritable bowel syndrome: Factors of importance for disease-specific quality of life. <i>United European Gastroenterology Journal</i> , 2022, 10, 754-764.	3.8	8
85	Centrally Targeted Pharmacotherapy for Chronic Abdominal Pain: Understanding and Management. <i>Handbook of Experimental Pharmacology</i> , 2016, 239, 417-440.	1.8	7
86	Psychopharmacologic Therapies for Irritable Bowel Syndrome. <i>Gastroenterology Clinics of North America</i> , 2021, 50, 655-669.	2.2	7
87	Gastrointestinal motility and neurogastroenterology. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 685-697.	1.5	6
88	In search for a disease-modifying treatment in irritable bowel syndrome. <i>Gut</i> , 2016, 65, 2-3.	12.1	6
89	Changes in serum and urinary metabolomic profile after a dietary intervention in patients with irritable bowel syndrome. <i>PLoS ONE</i> , 2021, 16, e0257331.	2.5	6
90	Online Education Is Non-Inferior to Group Education for Irritable Bowel Syndrome: A Randomized Trial and Patient Preference Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 743-751.e1.	4.4	5

#	ARTICLE	IF	CITATIONS
91	The diagnostic value of a change in bowel habit for colorectal cancer within different age groups. United European Gastroenterology Journal, 2020, 8, 211-219.	3.8	4
92	A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme Lactase on gastrointestinal symptoms in irritable bowel syndrome patients. Neurogastroenterology and Motility, 2021, 33, e14094.	3.0	4
93	A novel stepwise integrative analysis pipeline reveals distinct microbiota-host interactions and link to symptoms in irritable bowel syndrome. Scientific Reports, 2021, 11, 5521.	3.3	4
94	Altered Structural Covariance of Insula, Cerebellum and Prefrontal Cortex Is Associated with Somatic Symptom Levels in Irritable Bowel Syndrome (IBS). Brain Sciences, 2021, 11, 1580.	2.3	4
95	Maintaining work life under threat of symptoms: a grounded theory study of work life experiences in persons with Irritable Bowel Syndrome. BMC Gastroenterology, 2022, 22, 73.	2.0	4
96	Fecal luminal factors from patients with irritable bowel syndrome induce distinct gene expression of colonoids. Neurogastroenterology and Motility, 2022, 34, e14390.	3.0	4
97	Impact of symptom severity in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D): results from two separate surveys of HCPs and patients with IBS-D. BMC Gastroenterology, 2020, 20, 127.	2.0	3
98	Food-symptom diaries can generate personalized lifestyle advice for managing gastrointestinal symptoms: A pilot study. Neurogastroenterology and Motility, 2020, 32, e13820.	3.0	2
99	Authors' response: Bile acids are important in the pathophysiology of IBS. Gut, 2015, 64, 851.2-852.	12.1	1
100	Letter in response to Black et al. (2020). Neurogastroenterology and Motility, 2022, 34, e14329.	3.0	1
101	European guidelines on functional bowel disorders with diarrhoea: United European Gastroenterology (UEG) and European Society for neurogastroenterology and motility (ESNM) statements and recommendations. United European Gastroenterology Journal, 2022, 10, 615-616.	3.8	1
102	Reply. Clinical Gastroenterology and Hepatology, 2016, 14, 1222-1223.	4.4	0
103	Reply. Gastroenterology, 2016, 150, 1047-1048.	1.3	0
104	Reply. Clinical Gastroenterology and Hepatology, 2019, 17, 1002-1004.	4.4	0
105	Traditional treatments for irritable bowel syndrome: the state of our knowledge. The Lancet Gastroenterology and Hepatology, 2020, 5, 94-95.	8.1	0
106	Reply: The key to success: Targeting enzymes to their dietary counterpart. Neurogastroenterology and Motility, 2021, 33, e14203.	3.0	0
107	OTH-5...Functional gastrointestinal disorders and associated health impairment in individuals with coeliac disease. , 2021, , .		0
108	The Role of Carbohydrates in Irritable Bowel Syndrome: Protocol for a Randomized Controlled Trial Comparing Three Different Treatment Options. JMIR Research Protocols, 2022, 11, e31413.	1.0	0

#	ARTICLE	IF	CITATIONS
109	Editorial: group-based hypnotherapy as good as individually delivered hypnotherapy for symptoms of irritable bowel syndrome” authors’ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 160-161.	3.7	0